Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People

Long-term care facility (LTCF) older residents display physiological alterations of cellular and humoral immunity that affect vaccine responses. Preliminary reports suggested a low early postvaccination antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim o...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 778679
Main Authors Demaret, Julie, Corroyer-Simovic, Bénédicte, Alidjinou, Enagnon Kazali, Goffard, Anne, Trauet, Jacques, Miczek, Sophie, Vuotto, Fanny, Dendooven, Arnaud, Huvent-Grelle, Dominique, Podvin, Juliette, Dreuil, Daniel, Faure, Karine, Deplanque, Dominique, Bocket, Laurence, Duhamel, Alain, Labreuche, Julien, Sobaszek, Annie, Hisbergues, Michael, Puisieux, Francois, Labalette, Myriam, Lefèvre, Guillaume
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers 16.11.2021
Frontiers Media S.A
SeriesFrontiers in Immunology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Long-term care facility (LTCF) older residents display physiological alterations of cellular and humoral immunity that affect vaccine responses. Preliminary reports suggested a low early postvaccination antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to focus on the specific T-cell response. We quantified S1-specific IgG, neutralizing antibody titers, total specific IFNγ-secreting T cells by ELISpot, and functionality of CD4 - and CD8 -specific T cells by flow cytometry, after two doses of the BNT162b2 vaccine in younger and older people, with and without previous COVID-19 infection (hereafter referred to as COVID-19-recovered and COVID-19-naive subjects, respectively). Frailty, nutritional, and immunosenescence parameters were collected at baseline in COVID-19-naive older people. We analyzed the immune response in 129 young adults (median age 44.0 years) and 105 older residents living in a LCTF (median age 86.5 years), 3 months after the first injection. Humoral and cellular memory responses were dramatically impaired in the COVID-19-naive older (  = 54) compared with the COVID-19-naive younger adults (  = 121). Notably, older participants' neutralizing antibodies were 10 times lower than the younger's antibody titers (  < 0.0001) and LCTF residents also had an impaired functional T-cell response: the frequencies of IFNγ and IFNγ IL-2 TNFα cells among specific CD4 T cells, and the frequency of specific CD8 T cells were lower in COVID-19-naive older participants than in COVID-19-naive young adults (  < 0.0001 and  = 0.0018, respectively). However, COVID-19-recovered older participants (  = 51) had greater antibody and T-cell responses, including IFNγ and IFNγ IL-2 TNFα -specific CD4 T cells (  < 0.0001), as well as TNFα -specific CD8 T cells (  < 0.001), than COVID-19-naive older adults. We also observed that "inflammageing" and particularly high plasma levels of TNFα was associated to poor antibody response in the older participants. In conclusion, our results show that the COVID-19-naive older people had low counts and impaired specific CD4 and CD8 T cells, in addition to impaired antibody response, and that specific studies are warranted to assess the efficiency of SARS-CoV-2 mRNA-based vaccines, as in other immunocompromised subjects. Our study also shows that, despite their physiological alterations of immunity, vaccination is highly efficient in boosting the prior natural memory response in COVID-19-recovered older people.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC8637126
Edited by: Arun Kumar, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Reviewed by: Pradeep D. Uchil, Yale University, United States; Anmol Chandele, International Centre for Genetic Engineering and Biotechnology, India
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
These authors have contributed equally to this work and share last authorship
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.778679